Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting

Current Opinion in Anaesthesiology

Volumn 19, Issue 6, 2006, Pages 606-611

  Ho, Kok Yuen ^a   Gan, Tong J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

5 hydroxytryptamine type 3 receptor antagonists; Drug metabolism; Genetic polymorphism; Pharmacogenetics; Postoperative nausea and vomiting

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; DEXAMETHASONE; DOLASETRON MESILATE; GRANISETRON; HYDRODOLASETRON; ONDANSETRON; PALONOSETRON; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; TROPISETRON;

ANESTHESIST; ANTIEMETIC ACTIVITY; BINDING AFFINITY; CHEMOTHERAPY INDUCED EMESIS; COST EFFECTIVENESS ANALYSIS; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG SELECTIVITY; GENETIC POLYMORPHISM; HUMAN; OPTIMAL DRUG DOSE; PHARMACOGENETICS; POSTOPERATIVE NAUSEA AND VOMITING; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING;

ANTIEMETICS; CLINICAL TRIALS; CYTOCHROME P-450 CYP2D6; HUMANS; ORGANIC ANION TRANSPORTERS; PATIENT SELECTION; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POSTOPERATIVE NAUSEA AND VOMITING; RECEPTORS, SEROTONIN, 5-HT3; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 33750870359     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aco.0000247340.61815.38     Document Type: Review

References (52)

1. 3 receptor antagonists and the clinical implications of these differences.
2. Loewen PS, Marra CA, Zed PJ. 5-HT3 receptor antagonists vs traditional agents for the prophylaxis of postoperative nausea and vomiting. Can J Anaesth 2000; 47:1008-1018.
3. 3 receptor antagonists.
4. Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 1992; 77:162-184.
5. Anzemet (dolasetron mesylate) injection (prescribing information). Kansas City, MO. Aventis Pharmaceuticals Inc., 2005.
6. Kytril (granisetron hydrochloride) injection (prescribing information). Nutley, NJ. Roche Pharmaceuticals, 2006.
7. Zofran (ondansetron hydrochloride) injection premixed (prescribing information). Research Triangle Park, NC. GlaxoSmithKline, 2006.
8. Kees F, Farber L, Bucher M, et al. Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers. Br J Clin Pharmacol 2001; 52:705-707.
9. Fischer V, Baldeck JP, Tse FL. Pharmacokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans. Drug Metab Dispos 1992; 20:603-607.
10. Vickers AE, Fischer V, Connors MS, et al. Biotransformation of the antiemetic 5-HT3 antagonist tropisetron in liver and kidney slices of human, rat and dog with a comparison to in vivo. Eur J Drug Metab Pharmacokinet 1996; 21:43-50.
11. Aloxi (palonosetron hydrochloride) injection (prescribing information). Lugano, Switzerland. Helsinn Healthcare SA, 2006
12. Siddiqui MA, Scott LJ. Palonosetron. Drugs 2004; 64:1125-1132.
13. Novaban capsule injectie (tropisetron, prescribing information) [in Dutch]. Arnhem, Netherlands. Novartis Pharma B.V., 2003. Available at: http://www.novartis.nl. Accessed: 6 June 2006.
14. Upward JW, Arnold BD, Link C, et al. The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist. Eur J Cancer 1990; 26 (Suppl 1):S12-S15.
15. Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs 1998; 55:173-189.
16. Aapro M. Granisetron: an update on its clinical use in the management of nausea and vomiting. Oncologist 2004; 9:673-686.
17. 3 receptor antagonists and antiemetic efficacy.
18. Touw DJ. Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes. Drug Metabol Drug Interact 1997; 14:55-82.
19. Wolf CR, Smith G. Pharmacogenetics. Br Med Bull 1999; 55:366-386.
20. Fischer V, Vickers AE, Heitz F, et al. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 1994; 22:269-274.
21. Sanwald P, David M, Dow J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos 1996; 24:602-609.
22. Firkusny L, Kroemer HK, Eichelbaum M. In vitro characterization of cytochrome P450 catalysed metabolism of the antiemetic tropisetron. Biochem Pharmacol 1995; 49:1777-1784.
23. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60:284-295.
24. Mitsunaga Y, Kubota T, Ishiguro A, et al. Frequent occurrence of CYP2D6*10 duplication allele in a Japanese population. Mutat Res 2002; 505:83-85.
25. Bernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the US population: clinical implications. Oncologist 2006; 11:126-135. This article reviews variations in the prevalence of CYP2D6 polymorphism in the ethnically diverse American population.
26. Bathum L, Johansson I, Ingelman-Sundberg M, et al. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. Pharmacogenetics 1998; 8:119-123.
27. McLellan RA, Oscarson M, Seidegard J, et al. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997; 7:187-191.
28. Kaiser R, Sezer O, Papies A, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002; 20:2805-2811.
29. Candiotti KA, Birnbach DJ, Lubarsky DA, et al. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology 2005; 102:543-549. This clinical trial illustrates the association between CYP2D6 polymorphism and the lack of response to ondansetron prophylaxis.
30. Janicki PK, Schuler HG, Jarzembowski TM, Rossi M II. Prevention of postoperative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype. Anesth Analg 2006; 102:1127-1133. This is the first study that evaluates the therapeutic efficacy of granisetron and dolasetron in preventing PONV in patients based on the CYP2D6 metabolizer status.
31. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75:13-33.
32. 3 receptor antagonists in chemotherapy.
33. Dubin AE, Huvar R, D'Andrea MR, et al. The pharmacological and functional characteristics of the serotonin 5-HT(3A) receptor are specifically modified by a 5-HT(3B) receptor subunit. J Biol Chem 1999; 274:30799-30810.
34. Tremblay PB, Kaiser R, Sezer O, et al. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 2003; 21:2147-2155.
35. Kaiser R, Tremblay PB, Sezer O, et al. Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. Pharmacogenetics 2004; 14:271-278.
36. White PF, Tang J, Hamza MA, et al. The use of oral granisetron versus intravenous ondansetron for antiemetic prophylaxis in patients undergoing laparoscopic surgery: the effect on emetic symptoms and quality of recovery. Anesth Analg 2006; 102:1387-1393.
37. Gan TJ, Coop A, Philip BK. A randomized, double-blind study of granisetron plus dexamethasone versus ondansetron plus dexamethasone to prevent postoperative nausea and vomiting in patients undergoing abdominal hysterectomy. Anesth Analg 2005; 101:1323-1329.
38. Zarate E, Watcha MF, White PF, et al. A comparison of the costs and efficacy of ondansetron versus dolasetron for antiemetic prophylaxis. Anesth Analg 2000; 90:1352-1358.
39. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104:173-192.
40. Gan TJ. Risk factors for postoperative nausea and vomiting. Anesth Analg 2006; 102:1884-1898. This recent review article summarizes the literature on PONV in the past 15 years and provides an update on PONV risk factors.
41. Habib AS, White WD, Eubanks S, et al. A randomized comparison of a multimodal management strategy versus combination antiemetics for the prevention of postoperative nausea and vomiting. Anesth Analg 2004; 99:77-81.
42. Scuderi PE, James RL, Harris L, Mims GR III. Multimodal antiemetic management prevents early postoperative vomiting after outpatient laparoscopy. Anesth Analg 2000; 91:1408-1414.
43. Apfel CC, Laara E, Koivuranta M, et al. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999; 91:693-700.
44. Sinclair DR, Chung F, Mezei G. Can postoperative nausea and vomiting be predicted? Anesthesiology 1999; 91:109-118.
45. Koivuranta M, Laara E, Snare L, et al. A survey of postoperative nausea and vomiting. Anaesthesia 1997; 52:443-449.
46. Eberhart LH, Hogel J, Seeling W, et al. Evaluation of three risk scores to predict postoperative nausea and vomiting. Acta Anaesthesiol Scand 2000; 44:480-488.
47. Apfel CC, Kranke P, Eberhart LH, et al. Comparison of predictive models for postoperative nausea and vomiting. Br J Anaesth 2002; 88:234-240.
48. Gan TJ, Meyer T, Apfel CC, et al. Consensus guidelines for managing postoperative nausea and vomiting. Anesth Analg 2003; 97:62-71.
49. Habib AS, Gan TJ. Evidence-based management of postoperative nausea and vomiting: a review. Can J Anesth 2004; 51:326-341.
50. Pearman MH. Single dose intravenous ondansetron in the prevention of postoperative nausea and vomiting. Anaesthesia 1994; 49S:11-15.
51. Philip BK, McLeskey CH, Chelly JE, et al. Pooled analysis of three large clinical trials to determine the optimal dose of dolasetron mesylate needed to prevent postoperative nausea and vomiting. The Dolasetron Prophylaxis Study Group. J Clin Anesth 2000; 12:1-8.
52. Kovac AL, O'Connor TA, Pearman MH, et al. Efficacy of repeat intravenous dosing of ondansetron in controlling postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled multicenter trial. J Clin Anesth 1999; 11:453-459.